Sun Pharma agrees to acquire Organon in an all-cash deal valued at $11.75 billion
The Facts
- Sun Pharma has agreed to acquire Organon & Co. in an all-cash transaction with an enterprise value of about $11.75 billion, including debt.
- Under the agreement, Sun Pharma will pay $14 per share and acquire all outstanding shares of Organon.
- Organon was spun off from Merck in 2021 and focuses on areas including women's health and biosimilars.
- The acquisition is part of Sun Pharma's effort to expand its global business and strengthen its portfolio in specialty or innovative medicines.
- Multiple reports describe the transaction as the largest acquisition by an Indian pharmaceutical company or the largest overseas acquisition by an Indian pharmaceutical company.
- The transaction has been approved by both companies' boards but still requires customary regulatory approvals and approval from Organon shareholders.
- The companies have said they expect the deal to close in early 2027, subject to those approvals and other closing conditions.
Context
What does Sun Pharma get through this acquisition?
Sun Pharma would gain full ownership of Organon, a New Jersey-based healthcare company formed from Merck's 2021 spinoff that operates in women's health, biosimilars and established medicines Business Standard,CNBC,Hindu.
Why is Sun Pharma pursuing the deal now?
Reuters and other reports say Sun Pharma has been trying to build its higher-margin specialty and innovative medicines business and broaden its global reach, including in areas such as women's health and biosimilars Aol,Yahoo News,mint.
What still has to happen before the acquisition is completed?
The deal is not closed yet: it still needs regulatory clearance, approval from Organon shareholders and satisfaction of other customary closing conditions, with the companies targeting early 2027 for completion India Today,WSJ.
How left and right read it
What stands out is that a major cross-border deal would bring a company focused on women's health and biosimilars into a larger global strategy centered on specialty or innovative medicines. Because this is such a large transaction and still needs regulatory and shareholder approval, the public-interest question is whether that expansion ultimately strengthens access and patient-focused priorities in those areas.
This reads primarily as a strategic scale move: Sun Pharma is using an all-cash deal valued at about $11.75 billion, including debt, to expand its global business and strengthen its portfolio. The key issue is whether the transaction clears the required regulatory and shareholder approvals on the expected path to an early 2027 close, because process and execution matter in a deal of this size.
The receipts — all 117 sources
Wire services (4)
Independent coverage (50)
Facts first. Then every angle.
The day’s biggest stories in one short brief — the facts everyone agrees on, then the competing values behind the headlines. Free in your inbox.